# Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan

> **NCT02042014** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Severe Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** QTI571

## Key facts

- **NCT ID:** NCT02042014
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-22
- **Primary completion:** 2016-10-17
- **Final completion:** 2016-10-17
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042014, "Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02042014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*